Jundishapur Journal of Microbiology

Published by: Kowsar

The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran

Pegah Karimi Elizee 1 , 2 , 3 , Seyed Moayed Alavian 1 , 2 , 3 , * , Seyyed Mohammad Miri 1 , 2 , 3 , Bita Behnava 1 , 2 , 3 , Seyedeh Hoda Alavian 4 , Maryam Keshvari 5 , Mohammad Gholami Fesharaki 6 , Shima Salimi 2 , 3 , Leila Mehrnoush 2 , 3 and Mostafa Shafiei 2 , 3
Authors Information
1 Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver diseases, Tehran, IR Iran
2 Middle East Liver Disease Center, Tehran, IR Iran
3 Tehran Hepatitis Center, Tehran, IR Iran
4 Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
5 Iranian Blood Transfusion Organization research Center, Tehran, IR Iran
6 Biostatistics Department, Tarbiat Modarres University, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2013, 6 (7); e9091
  • Published Online: September 1, 2013
  • Article Type: Research Article
  • Received: November 11, 2012
  • Revised: February 19, 2013
  • Accepted: April 11, 2013
  • DOI: 10.5812/jjm.9091

To Cite: Karimi Elizee P, Alavian S M, Miri S M, Behnava B, Alavian S H, et al. The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran, Jundishapur J Microbiol. 2013 ; 6(7):e9091. doi: 10.5812/jjm.9091.

Abstract
Copyright © 2013, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Wasley A, Feinstone SM, Bell BP. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 2010; : 2367-89
  • 2. Anderson DA. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 2010; : 2411-23
  • 3. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol. 2001; 33(1): 20-6[PubMed]
  • 4. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009; 49(10): 2195-9[DOI][PubMed]
  • 5. Keshvari M, Alavian SM, Behnava B, Miri SM, Elizee PK, Tabatabaei SV, et al. Distribution of hepatitis C virus genotypes in iranian patients with congenital bleeding disorders. Iran Red Crescent Med J. 2010; 12(6): 608-14
  • 6. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8: 84-90
  • 7. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338(5): 286-90[DOI][PubMed]
  • 8. Cho HC, Paik SW, Kim YJ, Choi MS, Lee JH, Koh KC, et al. Seroprevalence of anti-HAV among patients with chronic viral liver disease. World J Gastroenterol. 2011; 17(2): 236-41[DOI][PubMed]
  • 9. Atiq M, Shire NJ, Barrett A, Rouster SD, Sherman KE, Shata MT. Hepatitis E virus antibodies in patients with chronic liver disease. Emerg Infect Dis. 2009; 15(3): 479-81[DOI][PubMed]
  • 10. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit. 2003; 9(1)-22[PubMed]
  • 11. Siagris D, Kouraklis-Symeonidis A, Konstantinidou I, Christofidou M, Starakis I, Lekkou A, et al. Prevalence of anti-HAV antibodies in multitransfused patients with beta-thalassemia. World J Gastroenterol. 2008; 14(10): 1559-63[PubMed]
  • 12. Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. East Mediterr Health J. 2011; 17(10): 754-8[PubMed]
  • 13. Vilibic-Cavlek T, Kucinar J, Ljubin-Sternak S, Kolaric B. Seroepidemiology of hepatitis a in the croatian population. Hepat Mon. 2011; 11(12): 997-9[DOI][PubMed]
  • 14. Luksamijarulkul P, Sujirarat D, Charupoonphol P. Risk Behaviors, Occupational Risk and Seroprevalence of Hepatitis B and A Infections among Public Cleansing Workers of Bangkok Metropolis . Hepat Mon. 2008; 8(1): 35-40
  • 15. Ghorbani GA. Is evaluation of hepatitis a immunity required or not? Hepat Mon. 2011; 11(12): 955-7[DOI][PubMed]
  • 16. Scaraggi FA, Perricci A, Petronelli M, Lomuscio S, De Mitrio V, Schiraldi O. Prevalence of serum IgG antibodies to hepatitis A virus in Italian haemophiliacs. Lancet. 1992; 339(8807): 1486-7[PubMed]
  • 17. Mosley JW. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States? Vox Sang. 1994; 67 Suppl 4: 12-5[PubMed]
  • 18. Kreuz W, Klarmann D, Auerswald G, Auberger K, Gurtler L, Rabenau H, et al. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease. Lancet. 1993; 341(8842): 446[PubMed]
  • 19. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994; 271(17): 1328-34[PubMed]
  • 20. Mohebbi SR, Rostami Nejad M, Tahaei SM, Pourhoseingholi MA, Habibi M, Azimzadeh P, et al. Seroepidemiology of hepatitis A and E virus infections in Tehran, Iran: a population based study. Trans R Soc Trop Med Hyg. 2012; 106(9): 528-31[DOI][PubMed]
  • 21. Saffar MJ, Abedian O, Ajami A, Abedian F, Mirabi AM, Khalilian AR, et al. Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review. Hepat Mon. 2012; 12(5): 326-32[DOI][PubMed]
  • 22. Ghadir MR, Jafari E, Rezvan H, Amini-Kafiabad S, Vaeze-Javadi M, Pourshams A. Hepatitis A and E in the east of Golestan province. J Med Council I.R.I. 2007; 25(1): 34-8
  • 23. Taghavi SA, Hosseini Asl MK, Talebzadeh M, Eshraghian A. Seroprevalence study of hepatitis A virus in Fars province, southern Iran. Hepat Mon. 2011; 11(4): 285-8[PubMed]
  • 24. Shoaei P, Zeidabadinejad L, Hassannejad R, Ataei B, Yaran M, Kassaian N, et al. Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province. Int J Prev Med. 2012; 3-6[PubMed]
  • 25. Johnson Z, Thornton L, Tobin A, Lawlor E, Power J, Hillary I, et al. An outbreak of hepatitis A among Irish haemophiliacs. Int J Epidemiol. 1995; 24(4): 821-8[PubMed]
  • 26. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998; 38(6): 573-9[PubMed]
  • 27. Brackmann HH, Oldenburg J, Eis-Hubinger AM, Gerritzen A, Hammerstein U, Hanfland P. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang. 1994; 67 Suppl 1: 3-7[PubMed]
  • 28. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med. 1994; 120(1): 1-7[PubMed]
  • 29. Kedda MA, Kew MC, Cohn RJ, Field SP, Schwyzer R, Song E, et al. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology. 1995; 22(5): 1363-7[PubMed]
  • 30. Normann A, Graff J, Gerritzen A, Brackmann HH, Flehmig B. Detection of hepatitis A virus RNA in commercially available factor VIII preparation. Lancet. 1992; 340(8829): 1232-3[PubMed]
  • 31. Steele M, Cochrane A, Wakefield C, Stain AM, Ling S, Blanchette V, et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia. 2009; 15(2): 437-47[DOI][PubMed]
  • 32. Chambost H, Doncarli A, Bertrand MA, Briquel ME, Gay V, Pincemaille O, et al. Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort. Haemophilia. 2007; 13(6): 712-21[DOI][PubMed]
  • 33. Hayashi K, Fukuda Y, Nakano I, Katano Y, Nagano K, Yokozaki S, et al. Infection of hepatitis A virus in Japanese haemophiliacs. J Infect. 2001; 42(1): 57-60[DOI][PubMed]
  • 34. Toyoda H, Honda T, Hayashi K, Katano Y, Goto H, Kumada T, et al. Prevalence of hepatitis E virus IgG antibody in Japanese patients with hemophilia. Intervirology. 2008; 51(1): 21-5[DOI][PubMed]
  • 35. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 2009; 24(9): 1484-93[DOI][PubMed]
  • 36. Ariyegan M, Amini S. Hepatitis E epidemic in Iran. J Med Council I.R. Irn . 1998; 15: 139-43
  • 37. Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmodi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. East Mediterr Health J. 2009; 15(1): 136-42[PubMed]
  • 38. Ataei B, Nokhodian Z, Javadi AA, Kassaian N, Shoaei P, Farajzadegan Z, et al. Hepatitis E virus in Isfahan Province: a population-based study. Int J Infect Dis. 2009; 13(1): 67-71[DOI][PubMed]
  • 39. Taremi M, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. East Mediterr Health J. 2007; 13(1): 98-102[PubMed]
  • 40. Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SA. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran. Int J Infect Dis. 2008; 12(4): 387-90[DOI][PubMed]
  • 41. Shamsizadeh A, Nikfar R, Makvandi M, Shamsizadeh N. Seroprevalence of Hepatitis E Virus Infection in Children in the Southwest of Iran. Hepat Mon. 2009; 9(4): 261-4
  • 42. Taremi M, Mohammad Alizadeh AH, Ardalan A, Ansari S, Zali MR. Seroprevalence of hepatitis E in Nahavand, Islamic Republic of Iran: a population-based study. East Mediterr Health J. 2008; 14(1): 157-62[PubMed]
  • 43. Rostamzadeh Khameneh Z, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients. Hepat Mon. 2011; 11(8): 646-51[PubMed]
  • 44. al-Fawaz I, al-Rasheed S, al-Mugeiren M, al-Salloum A, al-Sohaibani M, Ramia S. Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion. J Viral Hepat. 1996; 3(4): 203-5[PubMed]
  • 45. Mannucci PM, Gringeri A, Santagostino E, Romano L, Zanetti A. Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates. Lancet. 1994; 343(8897): 597-8[PubMed]
  • 46. Klarmann D, Kreuz W, Kornhuber B. Low prevalence of hepatitis E virus antibodies in hepatitis C virus-positive patients with coagulation disorders. Transfusion. 1995; 35(11): 969-70[PubMed]
  • 47. Zaaijer HL, Mauser-Bunschoten EP, ten Veen JH, Kapprell HP, Kok M, van den Berg HM, et al. Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients. J Med Virol. 1995; 46(3): 244-6[PubMed]
  • 48. Barzilai A, Schulman S, Karetnyi YV, Favorov MO, Levin E, Mendelson E, et al. Hepatitis E virus infection in hemophiliacs. J Med Virol. 1995; 46(2): 153-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments